null

null

null

null

null

null

null

null

null

null

null

null

null

0.10x Total Debt / Equity (Conservative)

Low direct sensitivity; minimal long-term debt, primarily equity-financed with ~$150M cash runway; 200bps rate rise modestly increases cost of any future debt financing

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) API/active pharmaceutical ingredient sourcing from China/India; 2) single-source CDMOs concentrated in North America for topical formulations

Minimal international revenue exposure; essentially US-only clinical/commercial stage company; sovereign currency devaluation risk is negligible at current scale

Predominantly US-based operations and revenue; no material international commercial presence; currency devaluation risk near zero across foreign markets

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High; Aclaris relies on single or dual-source CDMOs for drug manufacturing; substitution would require 12-24 months regulatory revalidation, exceeding 30% input cost threshold

Clinical-stage biopharma; cloud disruption would cause operational delays but not existential failure; core IP and manufacturing are non-cloud-dependent assets

Royalty and licensing model emerging via partnered assets; cloud termination would disrupt data systems but licensing contracts remain legally intact

Low API coupling risk; Aclaris uses standard cloud/SaaS tools without deep proprietary API integrations; clinical data platforms (Veeva, Medidata) have switching costs but are substitutable

Low Howey risk; revenue derived from drug sales and licensing, not investment contracts; equity securities are standard registered shares, not tokens or profit-sharing instruments

Very High

Moderate GDPR/CCPA exposure; clinical trial patient data requires strict compliance; US-centric operations limit GDPR scope, but any EU trial sites trigger full GDPR obligations

Low antitrust risk; niche dermatology/immunology pipeline with no dominant market share; no platform monopoly characteristics; standard pharmaceutical IP protections apply

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Primarily transactional/milestone-based; ESKATA discontinued; current revenue mix ~80% non-recurring (milestones, grants) and ~20% recurring royalty streams from partnered assets

Drug licensing milestones and royalties from partnered compounds (e.g., ATI-501 legacy); transitioning toward proprietary commercial product sales if pipeline succeeds

Price-sensitive dermatology market; topical JAK inhibitors face competition from Pfizer/Eli Lilly; pricing power constrained by biosimilar and generic pressure within 5-7 years of launch

Moderate-low; 3/10; specialty pharma pricing subject to PBM negotiation, formulary placement risk, and growing political pressure on drug pricing; limited orphan-drug premium potential

41.4% Gross Margin (Strong (40-60%))

No free-rider problem applicable; pharmaceutical product model with IP protection; off-label prescribing is minor leakage vector but not structurally significant

Sublinear at scale; drug commercialization requires salesforce build (linear phase) then plateaus; R&D headcount grows slower than pipeline value once platform established

Moderate marginal cost; manufacturing COGS scales with volume but R&D costs are largely sunk; doubling revenue at commercial stage requires ~30-40% headcount increase, not doubling

Not applicable; Aclaris operates no franchise network; standard pharmaceutical regulatory compliance (FDA, DEA) applies without franchise drift risk

At 10x scale, CAC economics improve via established physician relationships and brand recognition; sales rep productivity increases ~2-3x with matured formulary access and prescriber loyalty

No meaningful network effects; pharmaceutical adoption driven by clinical data and physician relationships, not user-base size; each prescription decision is independent

-40.5% Return on Assets (Negative equity)

Tier 3 (moderate vulnerability); specialty dermatology treatments are semi-elective; alopecia areata treatments may see volume decline in severe recessions as patients defer treatment

Dermatologists and rheumatologists (prescribers); no single physician group represents >5% of volume; moderate concentration risk via large health system formulary gatekeepers

Patients with alopecia areata and inflammatory skin conditions; payer concentration risk significant as top-3 PBMs (Express Scripts, CVS Caremark, OptumRx) control formulary access for ~80% of covered lives

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

1.4% CapEx / Revenue (Low-CapEx Asset-Light)

0001557746

ACRS